Microneedle patches for long-lasting HIV medication delivery
Official title: Self-administered microneedle patch for long-acting release of antiretroviral agents
Funded at Emory University · NIH-11134673 · Data updated 2026-11-12
This study is testing new biodegradable patches that can deliver HIV medication without needles, making it easier for people to take their medicine once a month or even less often, which is especially helpful for those who may not have easy access to healthcare.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | July 8, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $196,188 |
| NIH project number | 5R21AI186628-02 |
| Project ID | NIH-11134673 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals living with HIV who struggle with daily medication adherence or have limited access to healthcare.
✕Less likely to help
Patients who are not living with HIV or those who do not require antiretroviral therapy may not benefit from this research.
What this research studies
This research focuses on developing biodegradable microneedle patches that can self-administer antiretroviral agents (ARVs) for the treatment of HIV. The patches aim to provide a long-acting release of medication, reducing the need for daily doses and improving adherence to treatment. By encapsulating a potent ARV called Islatravir, the patches could allow for monthly or longer dosing intervals, making it easier for patients to manage their treatment. This approach is particularly beneficial for populations with limited access to healthcare, such as those in sub-Saharan Africa.
Why it matters
Potential benefit: If successful, this research could significantly improve medication adherence and quality of life for people living with HIV.
How similar studies have gone: Other research has shown promise in developing long-acting formulations for HIV treatment, but the specific combination of self-administered microneedle patches is a novel approach.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Tao, Sijia — Emory University
- Study coordinator: Tao, Sijia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.